Back to Search Start Over

Genomic Analysis of Historical Cases with Positive Newborn Screens for Short-Chain Acyl-CoA Dehydrogenase Deficiency Shows That a Validated Second-Tier Biochemical Test Can Replace Future Sequencing.

Authors :
Adhikari AN
Currier RJ
Tang H
Turgeon CT
Nussbaum RL
Srinivasan R
Sunderam U
Kwok PY
Brenner SE
Gavrilov D
Puck JM
Gallagher R
Source :
International journal of neonatal screening [Int J Neonatal Screen] 2020 Jun; Vol. 6 (2). Date of Electronic Publication: 2020 May 26.
Publication Year :
2020

Abstract

Short-chain acyl-CoA dehydrogenase deficiency (SCADD) is a rare autosomal recessive disorder of β-oxidation caused by pathogenic variants in the ACADS gene. Analyte testing for SCADD in blood and urine, including newborn screening (NBS) using tandem mass spectrometry (MS/MS) on dried blood spots (DBSs), is complicated by the presence of two relatively common ACADS variants (c.625G>A and c.511C>T). Individuals homozygous for these variants or compound heterozygous do not have clinical disease but do have reduced short-chain acyl-CoA dehydrogenase (SCAD) activity, resulting in elevated blood and urine metabolites. As part of a larger study of the potential role of exome sequencing in NBS in California, we reviewed ACADS sequence and MS/MS data from DBSs from a cohort of 74 patients identified to have SCADD. Of this cohort, approximately 60% had one or more of the common variants and did not have the two rare variants, and thus would need no further testing. Retrospective analysis of ethylmalonic acid, glutaric acid, 2-hydroxyglutaric acid, 3-hydroxyglutaric acid, and methylsuccinic acid demonstrated that second-tier testing applied before the release of the newborn screening result could reduce referrals by over 50% and improve the positive predictive value for SCADD to above 75%.<br />Competing Interests: Conflicts of Interest: A.N.A. is currently an employee of Illumina, Inc. U.S. and R.S. are employees of Tata Consultancy Services (TCS). R.L.N. is an employee of Invitae. J.M.P. is the spouse of R.L.N., who is an employee of Invitae. S.E.B. receives support at the University of California Berkeley from a research agreement from TCS. The remaining authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Details

Language :
English
ISSN :
2409-515X
Volume :
6
Issue :
2
Database :
MEDLINE
Journal :
International journal of neonatal screening
Publication Type :
Academic Journal
Accession number :
32802992
Full Text :
https://doi.org/10.3390/ijns6020041